Literature DB >> 21532885

Sulfated hexasaccharides attenuate metastasis by inhibition of P-selectin and heparanase.

Lubor Borsig1, Israel Vlodavsky, Rivka Ishai-Michaeli, Giangiacomo Torri, Elena Vismara.   

Abstract

Development of compounds that target both heparanase and selectins is emerging as a promising approach for cancer therapy. Selectins are vascular cell adhesion molecules that mediate tumor cell interactions with platelets, leukocytes, and the vascular endothelium. Heparanase is an endoglycosidase that degrades heparan sulfate in the tumor microenvironment, cell surfaces, and vessel wall. Acting together, these molecules facilitate tumor cell arrest, extravasation, and metastasis. Here, we report the preparation of novel semisynthetic sulfated tri mannose C-C-linked dimers (STMCs) endowed with heparanase and selectin inhibitory activity. The P-selectin specificity of the STMC was defined by the anomeric linkage of the C-C bond. This STMC hexasaccharide is an effective inhibitor of P-selectin in vivo. We show that selective inhibition of heparanase attenuates metastasis in B16-BL6 melanoma cells, expressing high levels of this endoglycosidase, but has no effect on the metastasis of MC-38 carcinoma cells that express little or no heparanase activity. P-selectin-specific STMC attenuated metastasis in both animal models, indicating that inhibition of tumor cell interaction with the vascular endothelium is critical for cancer dissemination. Thus, the small size, the stability of the C-C bond, and the chemically defined structure of the newly generated STMCs make them superior to heparin derivatives and signify STMCs as valuable candidates for further evaluation.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21532885      PMCID: PMC3084621          DOI: 10.1593/neo.101734

Source DB:  PubMed          Journal:  Neoplasia        ISSN: 1476-5586            Impact factor:   5.715


  61 in total

Review 1.  Proteoglycans in health and disease: new concepts for heparanase function in tumor progression and metastasis.

Authors:  Uri Barash; Victoria Cohen-Kaplan; Ilana Dowek; Ralph D Sanderson; Neta Ilan; Israel Vlodavsky
Journal:  FEBS J       Date:  2010-08-31       Impact factor: 5.542

Review 2.  Regulation, function and clinical significance of heparanase in cancer metastasis and angiogenesis.

Authors:  Neta Ilan; Michael Elkin; Israel Vlodavsky
Journal:  Int J Biochem Cell Biol       Date:  2006-07-06       Impact factor: 5.085

Review 3.  Non-anticoagulant heparins and inhibition of cancer.

Authors:  Benito Casu; Israel Vlodavsky; Ralph D Sanderson
Journal:  Pathophysiol Haemost Thromb       Date:  2009-01-27

4.  The PG500 series: novel heparan sulfate mimetics as potent angiogenesis and heparanase inhibitors for cancer therapy.

Authors:  K Dredge; E Hammond; K Davis; C P Li; L Liu; K Johnstone; P Handley; N Wimmer; T J Gonda; A Gautam; V Ferro; I Bytheway
Journal:  Invest New Drugs       Date:  2009-04-09       Impact factor: 3.850

Review 5.  Control of angiogenesis by heparin and other sulfated polysaccharides.

Authors:  J Folkman; Y Shing
Journal:  Adv Exp Med Biol       Date:  1992       Impact factor: 2.622

Review 6.  Heparins attenuate cancer metastasis: are selectins the link?

Authors:  Heinz Laubli; Lubor Borsig
Journal:  Cancer Invest       Date:  2009-06       Impact factor: 2.176

7.  P-selectin- and heparanase-dependent antimetastatic activity of non-anticoagulant heparins.

Authors:  Nina Hostettler; Annamaria Naggi; Giangiacomo Torri; Riva Ishai-Michaeli; Benito Casu; Israel Vlodavsky; Lubor Borsig
Journal:  FASEB J       Date:  2007-06-08       Impact factor: 5.191

8.  Inhibition of heparanase-mediated degradation of extracellular matrix heparan sulfate by non-anticoagulant heparin species.

Authors:  M Bar-Ner; A Eldor; L Wasserman; Y Matzner; I R Cohen; Z Fuks; I Vlodavsky
Journal:  Blood       Date:  1987-08       Impact factor: 22.113

Review 9.  Antimetastatic activities of modified heparins: selectin inhibition by heparin attenuates metastasis.

Authors:  Lubor Borsig
Journal:  Semin Thromb Hemost       Date:  2007-07       Impact factor: 4.180

Review 10.  Heparanase: structure, biological functions, and inhibition by heparin-derived mimetics of heparan sulfate.

Authors:  Israel Vlodavsky; Neta Ilan; Annamaria Naggi; Benito Casu
Journal:  Curr Pharm Des       Date:  2007       Impact factor: 3.116

View more
  20 in total

1.  The interconnectedness of cancer cell signaling.

Authors:  Alnawaz Rehemtulla
Journal:  Neoplasia       Date:  2011-12       Impact factor: 5.715

2.  Conformational changes of 1-4-glucopyranosyl residues of a sulfated C-C linked hexasaccharide.

Authors:  Alessia Coletti; Stefano Elli; Eleonora Macchi; Patrizia Galzerano; Leila Zamani; Marco Guerrini; Giangiacomo Torri; Elena Vismara
Journal:  Carbohydr Res       Date:  2014-02-25       Impact factor: 2.104

3.  Expression of metastasis suppressor BRMS1 in breast cancer cells results in a marked delay in cellular adhesion to matrix.

Authors:  Yekaterina B Khotskaya; Benjamin H Beck; Douglas R Hurst; Zhenbo Han; Weiya Xia; Mien-Chie Hung; Danny R Welch
Journal:  Mol Carcinog       Date:  2013-09-02       Impact factor: 4.784

4.  Cancer subclonal genetic architecture as a key to personalized medicine.

Authors:  Alnawaz Rehemtulla
Journal:  Neoplasia       Date:  2013-12       Impact factor: 5.715

5.  The potential of heparanase as a therapeutic target in cancer.

Authors:  Claudio Pisano; Israel Vlodavsky; Neta Ilan; Franco Zunino
Journal:  Biochem Pharmacol       Date:  2014-02-22       Impact factor: 5.858

Review 6.  Heparan sulfate signaling in cancer.

Authors:  Erik H Knelson; Jasmine C Nee; Gerard C Blobe
Journal:  Trends Biochem Sci       Date:  2014-04-19       Impact factor: 13.807

Review 7.  The role of heparins and nano-heparins as therapeutic tool in breast cancer.

Authors:  Nikos A Afratis; Konstantina Karamanou; Zoi Piperigkou; Demitrios H Vynios; Achilleas D Theocharis
Journal:  Glycoconj J       Date:  2016-10-24       Impact factor: 2.916

8.  Nanoparticles of a New Small-Molecule P-Selectin Inhibitor Attenuate Thrombosis, Inflammation, and Tumor Growth in Two Animal Models.

Authors:  Qiqi Feng; Mengyang Wang; Eldar Muhtar; Yaonan Wang; Haimei Zhu
Journal:  Int J Nanomedicine       Date:  2021-08-24

Review 9.  Metastasis review: from bench to bedside.

Authors:  Ali Mohammad Alizadeh; Sadaf Shiri; Sadaf Farsinejad
Journal:  Tumour Biol       Date:  2014-08-08

10.  Overcoming intratumor heterogeneity of polygenic cancer drug resistance with improved biomarker integration.

Authors:  Alnawaz Rehemtulla
Journal:  Neoplasia       Date:  2012-12       Impact factor: 5.715

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.